Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib Combinations in B-cell Malignancies
NCT02457598Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Jun 2015
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of tirabrutinib in follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL) and 4 more (17 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities up to 28 days, Objective Response Rate at Week 24 and 1 more. Started Jun 2015; status: terminated.
02
Drugs
tirabrutinib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)small lymphocytic lymphoma (SLL)chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02457598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02457598.